Osimertinib in Advanced Non–Small-Cell Lung Cancer
2 vistas
• 07/04/23
0
0
Empotrar
administrator
Suscriptores
EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios